Proinflammatory protein signatures in cryptogenic and large artery atherosclerosis stroke.


Journal

Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 29 06 2020
revised: 03 10 2020
accepted: 12 10 2020
pubmed: 28 10 2020
medline: 7 4 2021
entrez: 27 10 2020
Statut: ppublish

Résumé

The cause of ischemic stroke remains unknown, cryptogenic, in 25% of young and middle-aged patients. We hypothesized that if atherosclerosis is prominent in cryptogenic stroke, it would have a similar proinflammatory protein signature as large artery atherosclerosis (LAA) stroke. Blood was collected in the acute phase and after 3 months from cryptogenic (n = 162) and LAA (n = 73) stroke patients aged 18-69 years and once from age-matched controls (n = 235). Cryptogenic stroke was divided into Framingham Risk Score (FRS) quartiles to compare low and high risk of atherosclerosis. Plasma concentrations of 25 proteins were analyzed using a Luminex multiplex assay. The discriminating properties were assessed with discriminant analysis and C-statistics. We identified proteins that separated cryptogenic and LAA stroke from controls (area under the curves, AUCs ≥ 0.85). For both subtypes, RANTES, IL-4, and IFN-γ contributed the most at both time points. These associations were independent of risk factors of atherosclerosis. We also identified proteins that separated cryptogenic strokes in the lowest quartile of FRS from those in the highest, and from LAA stroke (AUCs ≥ 0.76), and here eotaxin and MCP-1 contributed the most. The protein signature separating cases from controls was different from the signature separating cryptogenic stroke with low risk of atherosclerosis from those with high risk and from LAA stroke. This suggests that increased RANTES, IL-4, and IFN-γ in stroke may not be primarily related to atherosclerosis, whereas increased eotaxin and MCP-1 in cryptogenic stroke may be markers of occult atherosclerosis as the underlying cause.

Identifiants

pubmed: 33107019
doi: 10.1111/ane.13366
pmc: PMC7898473
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

303-312

Subventions

Organisme : Hjärnfonden
ID : FO2017-0243
Organisme : Swedish Alzheimer Foundation
ID : AF-742881
Organisme : Rune and Ulla Amlöv's Foundation for Neurological Research
Organisme : European Union Joint Program for Neurodegenerative Disorders
ID : JPND2019-466-236
Organisme : Vetenskapsrådet
ID : 2018-02543
Organisme : The Swedish State under the agreement between the Swedish government and the county councils
ID : ALFGBG-715986
Organisme : Hjärt-Lungfonden
ID : 20190203
Organisme : Gothenburg Foundation for Neurological Research
Organisme : John och Brit Wennerströms Stiftelse för Neurologisk Forskning
Organisme : STROKE-Riksförbundet
Organisme : The Swedish State under the agreement between the Swedish government and the county councils
ID : ALFGBG-720211
Organisme : Knut och Alice Wallenbergs Stiftelse
Organisme : The Swedish State under the agreement between the Swedish government and the county councils
ID : ALFGBG-720081
Organisme : European Research Council
ID : 681712
Pays : International
Organisme : P-O Ahls´s Foundation for Neurological Research
Organisme : Alzheimer Drug Discovery Foundation
ID : RDAPB-201809-2016615
Organisme : Vetenskapsrådet
ID : 2017-00915
Organisme : The Swedish State under the agreement between the Swedish government and the county councils
ID : ALFGBG-720931

Informations de copyright

© 2020 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd.

Références

Circulation. 2005 Oct 18;112(16):2417-25
pubmed: 16230497
Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5252-6
pubmed: 2052604
Blood. 2001 Mar 15;97(6):1742-9
pubmed: 11238116
Curr Opin Pharmacol. 2016 Feb;26:26-32
pubmed: 26452204
Circulation. 2019 Jan 8;139(2):256-268
pubmed: 30586705
PLoS One. 2012;7(10):e47166
pubmed: 23077565
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
BMC Neurol. 2004 Jan 15;4:2
pubmed: 14725719
J Immunol. 1987 Jun 15;138(12):4490-5
pubmed: 3108393
Circulation. 2000 Oct 31;102(18):2185-9
pubmed: 11056090
PLoS One. 2007 May 23;2(5):e470
pubmed: 17520029
Ann Neurol. 1995 Jun;37(6):800-5
pubmed: 7778854
Circulation. 2006 Feb 14;113(6):791-8
pubmed: 16461820
J Clin Invest. 1991 Oct;88(4):1121-7
pubmed: 1843454
Int Immunopharmacol. 2011 Feb;11(2):157-63
pubmed: 21084063
Stroke. 2006 Aug;37(8):2018-23
pubmed: 16809555
Nature. 1998 Aug 27;394(6696):894-7
pubmed: 9732872
J Thromb Haemost. 2003 Feb;1(2):257-62
pubmed: 12871498
Brain Res. 2013 Jun 23;1517:122-32
pubmed: 23602964
Stroke. 2013 Feb;44(2):340-9
pubmed: 23306324
Biochem Biophys Res Commun. 1991 Sep 16;179(2):756-61
pubmed: 1716887
J Pathol. 1997 Nov;183(3):352-8
pubmed: 9422993
Eur J Neurol. 2013 Nov;20(11):1431-9
pubmed: 23837733
Transpl Int. 2013 Oct;26(10):1038-48
pubmed: 23952051
J Immunol. 2020 Jan 1;204(1):122-127
pubmed: 31767782
Front Neurol. 2017 Jan 19;8:6
pubmed: 28154551
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006 Apr;18(4):237-9
pubmed: 16647017
Int Immunol. 2010 May;22(5):347-52
pubmed: 20410258
Aging Dis. 2014 Oct 01;5(5):294-306
pubmed: 25276489
Cytokine. 2020 Feb;126:154923
pubmed: 31739217
Mediators Inflamm. 2006;2006(1):28398
pubmed: 16864900
Nat Immunol. 2009 Jul;10(7):706-12
pubmed: 19465908
Ann Rheum Dis. 2013 May;72(5):754-60
pubmed: 22915623
J Mol Neurosci. 2000 Jun;14(3):191-6
pubmed: 10984195
Transplantation. 2008 Sep 15;86(5):719-27
pubmed: 18791454
Stroke. 2012 Aug;43(8):2036-41
pubmed: 22627989
Mol Med. 2012 May 09;18:598-605
pubmed: 22331026
Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3450-6
pubmed: 19064561
Methods. 2012 Apr;56(4):464-70
pubmed: 22391487
Cardiovasc Revasc Med. 2016 Apr-May;17(3):169-75
pubmed: 27157293
Cerebrovasc Dis. 2009;27 Suppl 1:97-103
pubmed: 19342838
Stroke. 2005 Aug;36(8):1741-5
pubmed: 16020769
Stroke. 2005 Jul;36(7):1383-7
pubmed: 15933254
J Neurol Sci. 2005 Sep 15;236(1-2):65-71
pubmed: 15961109
Annu Rev Pathol. 2006;1:297-329
pubmed: 18039117
Neurology. 2011 Sep 20;77(12):1165-73
pubmed: 21849651
Exp Mol Med. 2016 Jan 08;48(1):e202
pubmed: 27534531
PLoS One. 2014 Sep 30;9(9):e105610
pubmed: 25268946
Blood. 2007 Jun 1;109(11):4786-92
pubmed: 17303692

Auteurs

Lukas Holmegaard (L)

Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Tara M Stanne (TM)

Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden.

Ulf Andreasson (U)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
UK Dementia Research Institute at UCL, London, UK.

Kaj Blennow (K)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Christian Blomstrand (C)

Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Katarina Jood (K)

Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Christina Jern (C)

Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH